What is the best "sleeper" biotech pick currently with potential, but essentially forgotten? | Biotech Message Board Posts

Biotech   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  33187 of 34971  at  7/2/2020 1:00:37 PM  by

Gary54

The following message was updated on 7/2/2020 2:36:20 PM.

 In response to msg 33159 by  Biotech_Jim
view thread

Re: What is the best "sleeper" biotech pick currently with potential, but essentially forgotten?

currently with potential, but essentially forgotten?
 
Tricida  TCDA
 
Nov. 14, 2019--
Tricida, Inc. (Nasdaq: TCDA), focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD)
 
It is an unmet need. 
 
~ 3 Million Patients with Metabolic Acidosis and CKD in the United States
 
Estimates of Revenues:  150,000 Rx Patients = $2 Billion 
 
Presentation             
 
 
CEO has started and sold two biotechs in his past.
 
Seasoned Commercial Officer hired from Gilead: 
While at Gilead, Susannah Cantrell, PhD led global marketing for YESCARTA, ZYDELIG and pre-launch activities for andecaliximab and the company’s chimeric antigen receptor T-Cell (CAR T) therapy portfolio.
 
50,000,000 shares: 80% Institutional Owned; Short 4.7 Million
 
CEO, some Directors use: Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2019. 
 
Cash:   Mar 31, 2020: $304 Million and raised $193 Million in May with 3.5% Convertible Senior Notes due 2027.
(Finra: Bond last sale at $104.61 on June 30, yield 2.7%) 
 
 Sleeper status:  Biotech board search produced three posts...
 
Stocktwits lists 322 watchers...(lowest of all the sleepers listed)
 
 
(PDUFA) goal date of August 22, 2020.
 
Will be a challenging time to bring a new drug to market with the Covid protocols of limited contact. 
 
I own shares.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 9     Views: 235
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
33197 Re: What is the best "sleeper" biotech pick currently with potential, but essentially forgotten? sleepingdog 1 7/2/2020 3:41:08 PM






Financial Market Data provided by
.
Loading...